Clinical Trials Logo

New Onset of Heart Failure clinical trials

View clinical trials related to New Onset of Heart Failure.

Filter by:
  • None
  • Page 1

NCT ID: NCT00525707 Completed - Acute Heart Failure Clinical Trials

Tezosentan in Acute Heart Failure

VERITAS 1
Start date: April 2003
Phase: Phase 3
Study type: Interventional

The randomized patients with acute heart failure will be stratified based on the presence or absence of a Swan-Ganz catheter and assigned to receive either tezosentan 5 mg/h for the first 30 minutes and 1 mg/h thereafter or matching placebo in a 1:1 manner. The duration of the treatment is 24 hours up to 72 hours. The duration of the follow-up period is 30 days after treatment initiation for death, re-hospitalizations and SAEs followed by a follow-up period of 5 months for vital status.

NCT ID: NCT00524433 Completed - Acute Heart Failure Clinical Trials

Tezosentan in the Treatment of Acute Heart Failure

VERITAS 2
Start date: April 2003
Phase: Phase 3
Study type: Interventional

The randomized patients with acute heart failure will be stratified based on the presence or absence of a Swan-Ganz catheter and assigned to receive either tezosentan 5 mg/h for the first 30 minutes and 1 mg/h thereafter or matching placebo in a 1:1 manner. The duration of the treatment is 24 hours up to 72 hours. The duration of the follow-up period is 30 days after treatment initiation for death, re-hospitalizations and SAEs followed by a follow-up period of 5 months for vital status.